Author name: Tianming Technical Team

Drawing from on-the-ground experience in China’s top pharma clusters, this guide cuts through the jargon to reveal when to partner for complex innovation and when to buy from the workhorses of mature production.

This case study, based on publicly available academic literature and patents, focuses on the application of synthetic route optimization in improving the yield and purity of Active Pharmaceutical Ingredients (APIs).

Learn how to manage hazardous reactions during intermediate synthesis with risk assessment, process control, and safety management strategies.

Compare continuous and batch manufacturing for pharmaceutical intermediates, focusing on cost, quality control, scalability, and supply chain risk.

Real-world insights into supply chain risk management for pharmaceutical intermediates, focusing on dual supply systems, critical raw material assurance, and compliance-driven supplier selection.

This article explains practical approaches to controlling residual metals through catalyst selection, reaction optimization, and downstream workup design.

This article shares practical insights on solvent choice, recovery feasibility, safety, and compliance based on real manufacturing experience.

This article shares practical, experience-based insights into how safety risks emerge during intermediate production and how they can be effectively managed through thoughtful process design, hazard evaluation, and operational controls.

Why more pharma companies outsource intermediate manufacturing is no longer just a cost question. Based on real project experience, this article explains how outsourcing intermediates helps drug developers improve speed, manage impurity risk, and maintain regulatory control while focusing on core innovation.